| 28077790 |
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
Levis, M,
Nguyen, B,
Williams, AB,
Small, D,
Brown, P,
Li, L,
Young, DJ,
Ma, H
|
Oncotarget |
2017 |
| 22354205 |
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
Pearson, AD,
Avery, S,
Workman, P,
Faisal, A,
Mair, D,
Atrash, B,
Blagg, J,
Bavetsias, V,
Linardopoulos, S,
Mirabella, F,
Valenti, M,
Eccles, SA,
Moore, AS,
de Haven Brandon, A,
Sun, C,
Swansbury, J,
Gonzalez de Castro, D,
Raynaud, FI
|
Leukemia |
2012 |
| 28522571 |
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia
Jäkel, H,
Duyster, J,
Nachbaur, D,
Götze, KS,
Sill, H,
Taschler, M,
Hengst, L,
Podmirseg, SR,
Peschel, I
|
Haematologica |
2017 |
| 22858906 |
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
Nguyen, B,
Brown, P,
Li, L,
Levis, M,
Williams, AB,
Leahy, D,
Small, D
|
Leukemia |
2013 |
| 24227820 |
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Levis, M,
Small, D,
Cortes, J,
Ramachandran, A,
Galanis, A,
Rajkhowa, T,
Ma, H
|
Blood |
2014 |
